Phase 2 RCT in 153 adults with moderate to severe hidradenitis suppurativa after anti-TNF failure: HiSCR50 at week 16 was 48.7% (300 mg weekly), 59.5% (300 mg every other week) and 27.0% (100 mg) with lutikizumab vs 35.0% with placebo.
RCTn = 153
Kimball et al. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial